Investigating the effect of beta-hydroxy beta-methylbutyrate in bariatric surgery

Evaluation the effect of beta-hydroxy beta-methylbutyrate supplementation on the prevention of postoperative sarcopenia in patients undergoing bariatric surgery: a double-blind clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200301046655N4

Enrollment

Registered

2023-08-28

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mini bypass surgery. Z98.84

Interventions

Intervention 1: Intervention group: They will receive beta-hydroxy beta-methylbutyrate (HMB) powder (Karen Company) at the rate of 3 grams per day for 30 days after surgery. Intervention 2: Control gr

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Candidate for mini bypass surgery Body mass index 40 to 50

Exclusion criteria

Exclusion criteria: Absence of severe hepatic impairment Absence of renal impairment Previous history of bariatric surgery

Design outcomes

Primary

Measure	Time frame
Muscle mass. Timepoint: Before surgery, 1, 3 and 6 months after surgery. Method of measurement: Bioimpedance analyzer.;Lean mass. Timepoint: Before surgery, 1, 3 and 6 months after surgery. Method of measurement: Bioimpedance analyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Khalooeifard

Tehran University of Medical Sciences

shkhalooei1367@gmail.com+98 21 6634 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026